Abstract: A core shell microcapsule having a liquid core and an outer shell, in which the liquid core comprises solvent and a piroctone compound and the shell comprises polyurea comprising amino sulphonic acid.

Abstract: A microcapsule composition useful in delivering an active material contains a first microcapsule and a second microcapsule. The first microcapsule has a zeta potential of 10 mV or greater, the second microcapsule has a zeta potential of 5 mV or less, and the weight ratio of the first microcapsule and the second microcapsule is between 1:10 and 10:1. Also disclosed are consumer products containing such a microcapsule composition.

Abstract: Disclosed herein are bioerodible drug delivery devices including one or more active agents, and related methods. The devices are useful for administering a wide variety of agents over prolonged periods of time.

Abstract: Disclosed are microcapsule compositions and their preparation methods. The microcapsule composition has a microcapsule dispersed in an aqueous phase. The microcapsule has a microcapsule core and a microcapsule wall encapsulating the microcapsule core. The microcapsule core contains an active material selected from the group consisting of a fragrance, cosmetic active, malodor counteractant, and combinations thereof. The microcapsule wall is formed of a polymeric network comprising of at least three moieties: (i) a first moiety derived from a chitosan, (ii) a second moiety derived from a polyisocyanate, and (iii) a third moiety derived from a polyphenol. Also disclosed are consumer products contain such a microcapsule composition.

Abstract: The object of the present disclosure is a method for treating keratinous material, in particular human hair, involving applying the following to the keratinous material a first composition (A) comprising, relative to the total weight of the composition (A) (A1) less than 10% by weight of water and (A2) one or more organic C1-C6 alkoxy silanes and/or their condensation products, and a second composition (B) comprising (B1) water and (B2) one or more terpenes.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: Disclosed is a modified biopolymer having the formula A-XY wherein: (a) A is a starting material selected from the group consisting of a polysaccharide, a protein and a cellulose; (b) X is a first moiety bearing a functionality co-reactive with A; (c) Y is a second moiety covalently bound to X, capable of undergoing free radical polymerization and bearing at least two ethylenically unsaturated functional groups; (d) the starting material A and the first moiety X are linked covalently through linkages selected from the group consisting of an ester, an amide, a urethane, a urea, a sulfonate ester, a phosphate ester and an ether; and (e) a degree of substitution of the starting material A with the first moiety X is less than 0.5 but more than 0.1. Compositions including the modified biopolymer and methods for making them are also disclosed.

Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture including an anti-cancer therapeutic and an antioxidant. The nanocarrier contains a porous silicate and/or aluminosilicate matrix and cerium oxide nanoparticles in the pores of the porous silicate and/or aluminosilicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

Abstract: The instant disclosure relates to essentially anhydrous hair-treatment compositions. The anhydrous hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more bis-urea derivatives; and one or more solvents. Additional components such as silicones, auxiliary agents, etc., can also be included. The instant disclosure also relates to kits that include the essentially anhydrous hair-treatment compositions and to methods for treating hair with the essentially anhydrous hair-treatment compositions.

Abstract: The present document describes a powder composition comprising a functionalized starch having a single helix V-structure and having a degree of substitution of at least 0.25, and a bioactive agent, forming an inclusion complex with said functionalized starch, where the bioactive agent is within the helix V-structure of the functionalized starch having a single helix V-structure. Also described are the functionalized starch having a single helix V-structure and having a degree of substitution of at least 0.25, methods of making the same and methods of using the same to manufacture the powder composition.

Abstract: The present invention relates to a pharmaceutical composition comprising an HDAC inhibitor, a pharmaceutically acceptable acid or salt thereof or a mixture of the acid and salt, provided both in a immediate release form and in an extended release form wherein 70-90 weight % of the HDAC inhibitor is provided in the immediate release form and the remainder of the HDAC inhibitor is provided in the extended release form. In further aspects the present invention relates to a kit comprising a number of doses of an HDAC inhibitor, a pharmaceutically acceptable acid or salt thereof or a mixture of the acid and salt thereof provided both in an immediate release form and in an extended release form.

Abstract: Disclosed are microcapsule compositions having microcapsules suspended in an aqueous phase. Each of the microcapsules has a single core-shell structure and contains a microcapsule core and a microcapsule wall encapsulating the microcapsule core. The microcapsule compositions include a pectin. Also disclosed are preparation methods and use of the microcapsule compositions in consumer products.

Abstract: The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine and one or more disinfectants, a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine, one or more disinfectants and one or more surfactants, a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine and one or more surfactants, a composition comprising, consisting essentially of, or consisting of one or more guanide-containing compound and one or more alcohols, kits comprising, consisting essentially of, or consisting of a disclosed composition, as well as methods and uses to clean, disinfect and/or sterilize a device using such compositions, methods and uses to clean, disinfect and/or sterilize a surface area using such compositions, methods and uses to clean, disinfect and/or sterilize a microbial infection in an individual using such composit

Abstract: Compositions and methods are provided for lamellar and defect reconstruction of corneal stromal tissue using biomaterials that form a defined gel structure in situ. Such gels can serve as cellular or acellular lamellar substitutes to reconstruct corneal stroma, facilitate matrix remodeling, and support multilayered re-epithelialization of wounded corneal stromal tissue, as well delivery vehicles for cells, biomolecules, and/or pharmaceutical agents to wound sites throughout the body.

Abstract: A directly compressible composition includes more than 30% by weight of allulose. The directly compressible composition can form tablets. A method for the manufacture of allulose granules includes: a step (a) of preparing a granulation liquid comprising allulose; a step (b) of granulating powdery allulose, by applying the granulation liquid obtained in step (a) onto moving powdery allulose; a step (c), simultaneous with step (b), of drying the granules obtained in step (b); a step (c?) of maturation of the granules obtained in step (c); and a step (d) of recovering the granules obtained in step (c) or (c?).

Abstract: The present invention provides an oral transmucosal film for delivering agomelatine through the buccal mucosa or sublingual mucosa. The film is a bilayer structure containing a mucoadhesive layer with amorphous agomelatine and a water-soluble backing layer without agomelatine. The film has improved bioavailability and improved palatability. The mucoadhesive layer comprises comprising 0.1%-40% by weight of amorphous agomelatine, or a pharmaceutical acceptable salt thereof, 50-98% by weight of a first film-forming material, 0.5-20% by weight of an oil phase excipient, and 0.5-17% by weight of a surfactant. The backing layer comprises 60-100% (w/w) of one or more film-forming agents.

Abstract: The present specification discloses a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine and one or more disinfectants, a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine, one or more disinfectants and one or more surfactants, a composition comprising, consisting essentially of, or consisting of hypochlorous acid or free available chlorine and one or more surfactants, a composition comprising, consisting essentially of, or consisting of one or more guanide-containing compound and one or more alcohols, kits comprising, consisting essentially of, or consisting of a disclosed composition, as well as methods and uses to clean, disinfect and/or sterilize a device using such compositions, methods and uses to clean, disinfect and/or sterilize a surface area using such compositions, methods and uses to clean, disinfect and/or sterilize a microbial infection in an individual using such composit

Abstract: Disclosed is a callus lysate containing a callus metabolite without a loss of callus metabolite and its preparation method, a capsule containing a callus lysate prepared through encapsulation by coating the callus lysate with a natural polymer material and its preparation method, and composition for external skin application and a cosmetic composition that includes the callus lysate or the capsule containing the callus lysate as an active ingredient, wherein the callus lysate of the present invention contains a large amount of a callus metabolite without a loss of callus metabolite and thus allows penetration or absorption of callus metabolite directly into the skin, thereby providing effects of the callus metabolite to prevent and improve various skin diseases and symptoms.

Abstract: A composition configured for oral use is provided, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.

Abstract: Microcapsules encapsulating oily core materials have a shell material of hybrid polyurea and poly(beta-amino esters) (PU/PBAE). The microcapsules may have a single shell of hybrid PU/PBAE, dual shells including hybrid PU/PBAE in an inner shell and PBAE in an outer shell crosslinked and deposited to the inner shell, or multiple shells including PU in an inner shell, hybrid PU/PBAE in a transitioning shell, and PBAE in an outer shell. Formation of the microcapsules includes polymerization between multifunctional amine and multifunctional acrylate to produce a water soluble PBAE; polymerization between polyisocyanate in oil phase and multifunctional amine in aqueous solution to produce PU microcapsule, polymerization between polyisocyanate and the amine moiety of PBAE prepolymer to produce hybrid PU/PBAE microcapsule wall; and polymerization between multifunctional acrylate and primary or secondary amine moiety of the PBAE prepolymer to form a PBAE outer shell.